Concord Biotech Ltd Stock Price Today (NSE: CONCORDBIO)
Fundamental Score
Concord Biotech Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Concord Biotech Ltd share price today is ₹1018.40, down 2.34% on NSE/BSE as of 30 March 2026. Concord Biotech Ltd (CONCORDBIO) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹14.96K (Cr). The 52-week high for CONCORDBIO share price is ₹2150.40 and the 52-week low is ₹995.10. At a P/E ratio of 46.19x, CONCORDBIO is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 21.27% and a debt-to-equity ratio of 0.00.
Concord Biotech Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Concord Biotech Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Concord Biotech Share Price Analysis: Navigating the Fermentation Landscape
The pharmaceutical sector, particularly in specialized segments like fermentation-based APIs, is experiencing a paradigm shift driven by increasing demand for complex and biosimilar drugs. This creates both opportunities and challenges for companies operating within this space. This financial analysis delves into the factors influencing the Concord Biotech share price, focusing on key financial metrics and competitive positioning. Currently trading at ₹1327.199951 with a PE ratio of 46.19, Concord Biotech presents an interesting case for investors.
A critical factor in assessing long-term potential is the company's Return on Capital Employed (ROCE) of 28.25%. This high ROCE indicates that Concord Biotech is effectively generating profit from its capital investments. In the context of the pharmaceutical industry, a consistently high ROCE like this contributes to the company’s "moat" by enabling them to reinvest earnings in research and development, capacity expansion, and strategic acquisitions, strengthening their competitive edge and potentially driving future growth.
When comparing Concord Biotech to its peers, considering qualitative factors is paramount. For instance, examining the quality of management at
Mankind Pharma Ltd and contrasting it with Concord Biotech’s leadership provides valuable insights into their respective strategic visions and operational efficiencies. A strong management team can significantly impact a company's ability to navigate regulatory hurdles, optimize manufacturing processes, and capitalize on market opportunities, ultimately affecting shareholder value.While the PE ratio of 46.19 suggests a premium valuation, this must be considered alongside the ROCE and future growth prospects within the API fermentation market. Further investigation into Concord Biotech’s debt levels, cash flow generation, and pipeline of new products is necessary to form a complete picture. This analysis is part of a comprehensive 80-parameter fundamental audit of Concord Biotech Ltd., verified by Sweta Mishra. This analysis is for informational purposes only and should not be construed as financial advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Concord Biotech Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of CONCORDBIO across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (21.27%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (28.25%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (42.73%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Consistent Growth Track Record (18.56% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (18.55% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (1342.00x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹428.88 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Premium Valuation Risk (P/E: 46.19x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-33.59%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-20.35%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Weak Earnings Growth (-26.61% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Concord Biotech Ltd Financial Statements
Comprehensive financial data for Concord Biotech Ltd including income statement, balance sheet and cash flow
About CONCORDBIO (Concord Biotech Ltd)
Concord Biotech Ltd is a pioneering force in the realm of biopharmaceutical innovation, dedicated to pushing the boundaries of drug development and manufacturing. At its core, the ...company is driven by a relentless pursuit of scientific excellence, meticulously crafting novel pharmaceutical solutions for a diverse range of global healthcare needs. With a steadfast commitment to research and development, Concord Biotech navigates the complexities of modern medicine, striving to deliver life-enhancing therapies that address critical medical challenges. Their unwavering dedication to quality and innovation positions them as a key player in the pharmaceutical landscape, constantly evolving to meet the ever-changing demands of the industry. Concord Biotech's expertise shines through in its specialized focus on fermentation-derived active pharmaceutical ingredients (APIs), particularly within the crucial therapeutic areas of immunosuppression, oncology, and infection control. By harnessing the power of microbial fermentation, the company meticulously cultivates and refines potent APIs, serving as the building blocks for transformative medications. Concord Biotech's deep understanding of fermentation processes allows it to develop and manufacture APIs with high precision and efficacy, ultimately impacting the lives of patients worldwide. This specialized focus, combined with rigorous quality control measures, solidifies Concord Biotech's reputation as a trusted provider of vital pharmaceutical components. Among its notable offerings, Concord Biotech boasts a portfolio of critical immunosuppressant APIs, playing a vital role in transplant medicine and the management of autoimmune disorders. These APIs, including tacrolimus, mycophenolate, cyclosporine, and sirolimus, are essential in preventing organ rejection and suppressing the immune system in various conditions. By ensuring a reliable supply of these crucial components, Concord Biotech actively contributes to the success of life-saving transplant procedures and the improved quality of life for patients battling immune-related diseases. This commitment to providing high-quality immunosuppressant APIs underscores Concord Biotech's dedication to meeting critical healthcare needs on a global scale.
Company Details
Key Leadership
Corporate Events
CONCORDBIO Share Price: Frequently Asked Questions
What is the current share price of Concord Biotech Ltd (CONCORDBIO)?
As of 30 Mar 2026, 12:02 pm IST, Concord Biotech Ltd share price is ₹1018.40. The CONCORDBIO stock has a market capitalisation of ₹14.96K (Cr) on NSE/BSE.
Is CONCORDBIO share price Overvalued or Undervalued?
CONCORDBIO share price is currently trading at a P/E ratio of 46.19x, compared to the industry average of 31.77x. Based on this relative valuation, the Concord Biotech Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of CONCORDBIO share price?
The 52-week high of CONCORDBIO share price is ₹2150.40 and the 52-week low is ₹995.10. These values are updated daily from NSE/BSE price data.
What factors affect the Concord Biotech Ltd share price?
Key factors influencing CONCORDBIO share price include quarterly earnings growth (Sales Growth: -20.35%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Concord Biotech Ltd a good stock for long-term investment?
Concord Biotech Ltd shows a 5-year Profit Growth of 18.55% and an ROE of 21.27%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing in CONCORDBIO shares.
How does Concord Biotech Ltd compare with its industry peers?
Concord Biotech Ltd competes with major peers in the Pharmaceuticals. Investors should compare CONCORDBIO share price P/E of 46.19x and ROE of 21.27% against the industry averages to determine competitive standing.
What is the P/E ratio of CONCORDBIO and what does it mean?
CONCORDBIO share price has a P/E ratio of 46.19x compared to the industry average of 31.77x. Investors pay ₹46 for every ₹1 of annual earnings.
How is CONCORDBIO performing according to Bull Run's analysis?
CONCORDBIO has a Bull Run fundamental score of 56.3/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does CONCORDBIO belong to?
CONCORDBIO operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Concord Biotech Ltd share price.
What is Return on Equity (ROE) and why is it important for CONCORDBIO?
CONCORDBIO has an ROE of 21.27%, which indicates excellent management efficiency. ROE measures how efficiently Concord Biotech Ltd generates profits from shareholders capital.
How is CONCORDBIO debt-to-equity ratio and what does it indicate?
CONCORDBIO has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk.
What is CONCORDBIO dividend yield and is it a good dividend stock?
CONCORDBIO offers a dividend yield of 0.75%, meaning you receive ₹0.75 annual dividend for every ₹100 invested in Concord Biotech Ltd shares.
How has CONCORDBIO share price grown over the past 5 years?
CONCORDBIO has achieved 5-year growth rates of: Sales Growth 18.56%, Profit Growth 18.55%, and EPS Growth -26.61%.
What is the promoter holding in CONCORDBIO and why does it matter?
Promoters hold 44.08% of CONCORDBIO shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Concord Biotech Ltd.
What is CONCORDBIO market capitalisation category?
CONCORDBIO has a market capitalisation of ₹14962 crores, placing it in the Mid-cap category.
How volatile is CONCORDBIO stock?
CONCORDBIO has a beta of N/A. A beta > 1 suggests the Concord Biotech Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is CONCORDBIO operating profit margin trend?
CONCORDBIO has a 5-year average Operating Profit Margin (OPM) of 42.73%, indicating the company's operational efficiency.
How is CONCORDBIO quarterly performance?
Recent quarterly performance shows Concord Biotech Ltd YoY Sales Growth of -20.35% and YoY Profit Growth of -33.59%.
What is the institutional holding pattern in CONCORDBIO?
CONCORDBIO has FII holding of 8.03% and DII holding of 9.55%. Significant institutional holding often suggests professional confidence in the Concord Biotech Ltd stock.